These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 1409415)

  • 21. Antigenic profile of tumor progression stages in human melanocytic nevi and melanomas.
    Elder DE; Rodeck U; Thurin J; Cardillo F; Clark WH; Stewart R; Herlyn M
    Cancer Res; 1989 Sep; 49(18):5091-6. PubMed ID: 2548711
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Analysis of hybridoma-exchange antibodies.
    Lloyd KO; Albino A; Houghton A
    Hybridoma; 1982; 1(4):461-3. PubMed ID: 6208140
    [No Abstract]   [Full Text] [Related]  

  • 23. A retrospective look at dysplastic nevi. What were they in 1978 and how have they fared since?
    Cockerell CJ; Berson DS
    Am J Dermatopathol; 1985; 7 Suppl():93-7. PubMed ID: 3940095
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The differential reactivity of benign and malignant nevomelanocytic lesions with mouse monoclonal antibody TNKH1.
    Nakanishi T; Hashimoto K
    Cancer; 1987 Apr; 59(7):1340-4. PubMed ID: 3545436
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Spontaneous regression of multiple melanocytic nevi after melanoma: report of 3 cases.
    Martín JM; Pinazo I; Monteagudo C; Markovic J; Allende A; Jordá E
    Am J Dermatopathol; 2014 Nov; 36(11):e183-8. PubMed ID: 25343215
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Origin of cutaneous melanoma in a congenital dysplastic nevus spilus.
    Rhodes AR; Mihm MC
    Arch Dermatol; 1990 Apr; 126(4):500-5. PubMed ID: 2321995
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Nodal melanocytic nevus with balloon-cell change (nodal balloon-cell nevus).
    Urso C
    J Cutan Pathol; 2008 Jul; 35(7):672-6. PubMed ID: 18312441
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Antigenic phenotype of pigment cell lesions: a study of melanoma, its precursor lesions and heterogeneity in metastatic melanoma.
    Ernstoff MS; Duray P; Stenn K; Kirkwood JM
    J Invest Dermatol; 1985 May; 84(5):430-2. PubMed ID: 3889169
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The anti-MAGE antibody B57 as a diagnostic marker in melanocytic lesions.
    Kazakov DV; Kutzner H; Rütten A; Michal M; Requena L; Burg G; Dummer R; Kempf W
    Am J Dermatopathol; 2004 Apr; 26(2):102-7. PubMed ID: 15024190
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Tumor antigen expression in compound dysplastic nevi and superficial spreading melanoma defined by a panel of nevomelanoma monoclonal antibodies.
    Lazzaro B; Strassburg A
    Hybridoma; 1996 Apr; 15(2):141-6. PubMed ID: 8743294
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Proliferative activity of cutaneous melanocytic neoplasms defined by a proliferating cell nuclear antigen labelling index.
    Tokuda Y; Mukai K; Matsuno Y; Furuya S; Shimosato Y; Takasaki Y; Saida T; Ishihara K
    Arch Dermatol Res; 1992; 284(6):319-23. PubMed ID: 1363460
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Histological analysis of intraepidermal proliferations of atypical melanocytes.
    Urso C; Giannini A; Bartolini M; Bondi R
    Am J Dermatopathol; 1990 Apr; 12(2):150-5. PubMed ID: 2331049
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The role of oncogenes and growth factors in progressive melanoma-genesis.
    Albino AP
    Pigment Cell Res; 1992; Suppl 2():199-218. PubMed ID: 1409423
    [No Abstract]   [Full Text] [Related]  

  • 34. The diagnostic reproducibility of melanocytic dysplasia.
    Piepkorn M
    Arch Dermatol; 1998 Aug; 134(8):1037-9. PubMed ID: 9722743
    [No Abstract]   [Full Text] [Related]  

  • 35. Development of MoAb HMSA-2 for melanosomes of human melanoma and its application to immunohistopathologic diagnosis of neoplastic melanocytes.
    Maeda K; Jimbow K
    Cancer; 1987 Feb; 59(3):415-23. PubMed ID: 3539311
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comparison of proliferative activity as assessed by proliferating cell nuclear antigen (PCNA) and Ki-67 monoclonal antibodies in melanocytic skin lesions. A quantitative immunohistochemical study.
    Rieger E; Hofmann-Wellenhof R; Soyer HP; Kofler R; Cerroni L; Smolle J; Kerl H
    J Cutan Pathol; 1993 Jun; 20(3):229-36. PubMed ID: 8103531
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Immunohistological detection of human malignant melanoma using monoclonal antibody to a melanoma-associated antigen.
    Kageshita T; Johno M; Ono T; Arao T; Imai K
    Arch Dermatol Res; 1985; 277(4):334-6. PubMed ID: 3890772
    [No Abstract]   [Full Text] [Related]  

  • 38. Distinguishing cancer and noncancer.
    Elder DE
    J Invest Dermatol; 1985 Jul; 85(1):1-3. PubMed ID: 4008973
    [No Abstract]   [Full Text] [Related]  

  • 39. From the melanocyte to melanoma to tumor biology.
    Clark WH
    Adv Cancer Res; 1994; 65():113-40. PubMed ID: 7879663
    [No Abstract]   [Full Text] [Related]  

  • 40. [Immuno-diagnosis of malignant melanoma].
    Szekeres G; Battyáni Z
    Magy Onkol; 2003; 47(1):45-50. PubMed ID: 12704454
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.